

## Appendix

### **Predictors of Transitioning to Incident Chronic Opioid Therapy Among Working-Aged Adults in the United States**

J. Douglas Thornton, PharmD, PhD; Nilanjana Dwibedi, PhD; Virginia Scott, PhD; Charles D. Ponte, PharmD; Douglas Ziedonis, MD; Nethra Sambamoorthi, PhD; Usha Sambamoorthi, PhD

This Appendix has not been edited and is provided as supplemental materials for this article, which was published in *American Health & Drug Benefits* in February 2018.

**Supplemental Table 1.** Logistic regression with adjusted odds ratio (AOR) and 95% confidence interval (95%CI) for patients with incident opioid use by transition to chronic opioid therapy after first opioid prescription, using IQVIA's Real World Data: Adjudicated Claims - US, 2006-2015

	<b>Model 1 in</b>			<b>Model 1 in</b>			<b>Fully-adjusted model in</b>			<b>Fully-adjusted model in</b>		
	<b>Training/Validation subsample</b>			<b>Test subsample</b>			<b>Training/ Validation subsample</b>			<b>Test subsample</b>		
	<b>AOR</b>	<b>95% CI</b>	<b>Sig</b>	<b>AOR</b>	<b>95% CI</b>	<b>Sig</b>	<b>AOR</b>	<b>95%CI</b>	<b>Sig</b>	<b>AOR</b>	<b>95% CI</b>	<b>Sig</b>
<b>Age</b> (continuous)	1.02	[1.02,1.02]	***	1.02	[1.02,1.03]	***	1.02	[1.01,1.02]	***	1.02	[1.01,1.03]	***
<b>Male</b> vs. Female	1.45	[1.37,1.53]	***	1.43	[1.27,1.60]	***	1.50	[1.41,1.59]	***	1.46	[1.30,1.65]	***
<b>Highly likely chronic pain</b> vs. None	5.98	[5.01,7.11]	***	5.91	[4.18,8.20]	***	5.59	[4.68,6.66]	***	5.47	[3.89,7.68]	***
<b>Likely chronic pain</b> vs. None	2.15	[2.02,2.27]	***	2.08	[1.84,2.34]	***	2.08	[1.96,2.21]	***	2.02	[1.79,2.28]	***
<b>Arthritis</b> vs. None	1.83	[1.68,1.98]	***	1.92	[1.63,2.25]	***	1.78	[1.64,1.93]	***	1.86	[1.58,2.20]	***
<b>Hydrocodone</b> vs. Codeine	2.19	[1.87,2.58]	***	2.04	[1.49,2.87]	***	2.15	[1.83,2.52]	***	1.97	[1.42,2.73]	***
<b>Oxycodone</b> vs. Codeine	2.52	[2.13,3.01]	***	2.70	[1.92,3.90]	***	2.53	[2.13,3.02]	***	2.67	[1.87,3.81]	***

**Supplemental Table 1.** Logistic regression with adjusted odds ratio (AOR) and 95% confidence interval (95%CI) for patients with incident opioid use by transition to chronic opioid therapy after first opioid prescription, using IQVIA's Real World Data: Adjudicated Claims - US, 2006-2015

	Model 1 in Training/Validation subsample			Model 1 in Test subsample			Fully-adjusted model in Training/ Validation subsample			Fully-adjusted model in Test subsample		
	AOR	95% CI	Sig	AOR	95% CI	Sig	AOR	95%CI	Sig	AOR	95% CI	Sig
<b>Tramadol</b> vs. Codeine	7.03	[5.99,8.31]	***	7.59	[5.53,10.74]	***	6.79	[5.77,8.01]	***	7.26	[5.20,10.13]	***
<b>All other opioids</b> vs. Codeine	6.03	[4.68,7.75]	***	5.71	[3.38,9.59]	***	5.89	[4.57,7.60]	***	5.64	[3.34,9.53]	***
<b>Long-acting</b> vs. Immediate release	16.01	[13.17,19.42]	***	12.43	[8.13,18.83]	***	16.08	[13.21,19.57]	***	12.28	[8.06,18.72]	***
<b>Moderate</b> vs. Low dose†	0.52	[0.47,0.57]	***	0.45	[0.37,0.55]	***	0.52	[0.47,0.57]	***	0.45	[0.37,0.54]	***
<b>High</b> vs. Low dose†	0.52	[0.41,0.65]	***	0.71	[0.47,1.05]		0.52	[0.41,0.65]	***	0.68	[0.45,1.02]	
<b>Very high</b> vs. Low dose†	1.77	[1.40,2.22]	***	1.27	[0.73,2.08]		1.72	[1.36,2.17]	***	1.24	[0.74,2.08]	
<b>Benzodiazepine prescription</b> vs. None	2.06	[1.90,2.22]	***	1.99	[1.69,2.33]	***	1.82	[1.67,1.97]	***	1.82	[1.54,2.16]	***
<b>Drug use disorder diagnosis</b> vs. None	8.17	[6.75,9.83]	***	4.96	[3.13,7.58]	***	6.32	[5.17,7.73]	***	4.02	[2.53,6.40]	***
<b>Self</b> vs. Spouse	--			--			0.96	[0.88,1.05]		0.84	[0.71,1.01]	
<b>Unknown</b> vs. Spouse	--			--			1.30	[1.19,1.42]	***	1.19	[1.00,1.43]	
<b>Other</b> vs. Spouse	--			--			0.82	[0.70,0.97]	*	0.93	[0.67,1.28]	
<b>PPO</b> vs. HMO	--			--			1.06	[0.96,1.16]		1.20	[0.99,1.46]	
<b>Other‡</b> vs. HMO	--			--			0.86	[0.77,0.96]	**	1.06	[0.84,1.34]	
<b>Midwest</b> vs. East	--			--			1.13	[1.03,1.24]	**	1.28	[1.06,1.55]	**
<b>South</b> vs. East	--			--			1.21	[1.11,1.32]	***	1.31	[1.08,1.58]	**

**Supplemental Table 1.** Logistic regression with adjusted odds ratio (AOR) and 95% confidence interval (95%CI) for patients with incident opioid use by transition to chronic opioid therapy after first opioid prescription, using IQVIA's Real World Data: Adjudicated Claims - US, 2006-2015

	Model 1 in			Model 1 in			Fully-adjusted model in			Fully-adjusted model in		
	Training/Validation subsample			Test subsample			Training/ Validation subsample			Test subsample		
	AOR	95% CI	Sig	AOR	95% CI	Sig	AOR	95%CI	Sig	AOR	95% CI	Sig
West vs. East	--			--			1.02	[0.90,1.15]		1.28	[0.99,1.64]	
<i>Continued</i>												
<b>Cardio-metabolic condition</b> vs. None	--			--			1.17	[1.10,1.25]	***	0.90	[0.79,1.03]	
<b>Mental illness</b> vs. None	--			--			1.34	[1.25,1.45]	***	0.78	[0.67,0.91]	**
<b>Asthma</b> vs. None	--			--			0.87	[0.76,1.00]	*	0.85	[0.64,1.13]	
<b>COPD</b> vs. None	--			--			1.24	[0.92,1.67]		1.66	[0.92,3.02]	
<b>Dementia</b> vs. None	--			--			1.33	[0.84,2.11]		1.75	[0.73,4.17]	
<b>Hepatitis</b> vs. None	--			--			1.55	[1.18,2.04]	**	1.94	[1.19,3.15]	**
<b>Osteoporosis</b> vs. None	--			--			1.44	[1.14,1.83]	**	1.04	[0.59,1.83]	
<b>Tobacco</b> vs. None	--			--			1.45	[1.29,1.64]	***	1.34	[1.04,1.73]	*
<b>Any alcohol abuse</b> vs. None	--			--			0.93	[0.73,1.18]		0.78	[0.45,1.34]	
<b>Acute pain condition</b> vs. None	--			--			0.86	[0.67,1.10]		0.95	[0.59,1.53]	
<b>Stimulant prescription</b> vs. None	--			--			1.65	[1.40,1.95]	***	1.33	[0.93,1.91]	
<b>Non-opioid analgesic</b> vs. None	--			--			1.06	[0.99,1.13]		1.14	[1.00,1.29]	*

**Supplemental Table 1.** Logistic regression with adjusted odds ratio (AOR) and 95% confidence interval (95%CI) for patients with incident opioid use by transition to chronic opioid therapy after first opioid prescription, using IQVIA's Real World Data: Adjudicated Claims - US, 2006-2015

	Model 1 in Training/Validation subsample			Model 1 in Test subsample			Fully-adjusted model in Training/ Validation subsample			Fully-adjusted model in Test subsample		
	AOR	95% CI	Sig	AOR	95% CI	Sig	AOR	95%CI	Sig	AOR	95% CI	Sig
<b>Polypharmacy vs. None</b>	--			--			1.09	[1.02,1.17]	*	1.03	[0.90,1.19]	


Note: This sample includes patients from IQVIA's Real World Data: Adjudicated Claims - US, which were identified between 2007 and 2015 and had enrollment between 2006-2015. These patients were between 28-63 years old, without cancer, had complete demographic information available, and had only one opioid prescription on the index date. Due to data use requirements, some categories were collapsed. These include insurance plan type and other opioids.

†: Doses of opioids were converted to a standardized dose (milligrams of morphine equivalent) using the Centers for Medicare and Medicaid Services conversion table.

‡: Other insurance types included fee-for-service, health savings account, and indemnity.

Significance:  $0 < p < 0.001 = ***$ ,  $0.001 \leq p < 0.01 = **$ ,  $0.01 \leq p < 0.05 = *$

**Supplemental Figure 1:** Receiver operator characteristic (ROC) curves for Model 1 (orange, AUC = 0.767) and Fully Adjusted Model 2 (purple, AUC = 0.778) using the training/validation subsamples



**Supplemental Figure 2.** Receiver operator characteristic (ROC) curves for Model 1 using the training/validation subsample (black, AUC = 0.767) and Model 1 using the test subsample (green, AUC = 0.776).

